Drug intelligence / Profile preview

SHR-A2102 + HRS4642 + adebrelimab

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SHR-A2102 + HRS4642 + adebrelimab is a combination therapy being investigated for the treatment of advanced or metastatic pancreatic cancer. The regimen consists of three distinct therapeutic agents developed by Jiangsu Hengrui Pharmaceuticals: SHR-A2102, an antibody-drug conjugate (ADC) targeting Nectin-4; HRS4642, a potent and selective small molecule inhibitor of the KRAS G12D mutation; and adebrelimab, a humanized monoclonal antibody that inhibits the programmed death-ligand 1 (PD-L1) checkpoint. This multi-pronged approach aims to leverage the cytotoxic effects of the ADC, the targeted inhibition of a key oncogenic driver (KRAS G12D), and the reactivation of the anti-tumor immune response. The combination is currently being evaluated in a phase 2 platform trial sponsored by Fudan University.

Other names: SHR-A2102 + HRS-4642 + adebrelimab

Targets

PVRL4 (Nectin cell adhesion molecule 4)KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on SHR-A2102 + HRS4642 + adebrelimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-A2102 + HRS4642 + adebrelimab.

Explore the full profile